Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Operating Margin?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Operating Margin is 
772.7M (1Y +7.37% )

ALXN Stock Price & Operating Margin

Operating Margin for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Operating Margin

chevron_right 2021 722.1M +655x *
( +27.2% / year avg)
chevron_left 1995 -1.1M
vertical_align_top Peak 775.8M +26.7x *
vertical_align_bottom Bottom -30.1M
arrow_drop_up # Up Years 20 20 of 27
years up.
arrow_drop_down # Down Years 7
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or -0.07x the rate relative to it's operating margin over the same period.
  • If ALXN grows it's stock at the same rate as it's operating margin (+27.2%/year) , it's stock price will grow +1,108% and hit $1205.54 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 20 years (0%) it's operating margin were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
5-Year Change 🚀
+138%$6.4BNet Revenue (Sales)
+181%$608.8MCost of Revenue (Sales)
+135%$5.8BGross Profit Margin
-1.58%3.62Gross Profit Margin Ratio
+78.1%$1.2BResearch and Development (R&D)
+109%$1.8BSelling, General, and Administrative (SG&A)
+91.1%$3.2BTotal Operating Expenses
+101%$3.8BCost & Expenses
+38.7%$110.8MInterest Expense/Income, Net
+51.0%$300.4MDepreciation & Amortization (D&A)
+191%$2.9BEBITDA
+22.2%1.81EBITDA Margin
+227%$2.6BOperating Income
+37.0%1.63Operating Margin
-25.4%-$114.8MTotal Other Income/Expenses
+323%$2.4BPretax Income (Earnings)
+77.5%1.48Pretax Income (Earnings) Margin
-83.0%$219.2MProvision For Income Taxes
-391.6%$2.1BNet Income (Earnings)
-222.1%1.35Net Profit Margin
-401.9%9.78Earnings Per Share (EPS)
-401.9%9.78Earnings Per Share (EPS) Diluted
-3.15%$876.4MShares Outstanding
-3.15%$876.4MShares Outstanding (Diluted)
+154%$11.9BCash and Cash Equivalents
-88.2%$139.6MShort Term Investments
+105%$12.0BCash And Short-Term Investments
+227%$3.1BInventory
+135%$23.3BTotal Current Assets
+136%$5.8BPP&E
+1.69%$20.4BGoodwill
-37.3%$12.0BIntangible Assets
-17.4%$32.4BGoodwill and Intangible Assets
+37.6%$72.4BTotal Assets
+152%$474.4MAccounts Payables
-18.6%$569.6MShort-term Debt
+6,334%$1.1BOther Current Liabilities
+111%$6.5BTotal Current Liabilities
-27.2%$9.7BLong-term Debt
+291%$6.5BDeferred Tax Liabilities Non-Current
+147%$2.4BOther Non-Current Liabilities
+16.8%$19.3BTotal Non-Current Liabilities
+31.7%$25.8BTotal Liabilities
+370%$21.0BRetained Earnings
-331.5%-$500.0MAccumulated Other Comprehensive Income Loss
+41.2%$46.6BTotal Shareholders Equity
+37.6%$72.4BTotal Liabilities & Stockholders Equity
-26.8%$10.2BTotal Debt
-117.2%-$1.6BNet Debt
-128.0%-$436.8MDeferred Income Tax
+67.5%$342.0MStock-Based Compensation (SBC)
-1,029.8%$1.9BChange in Working Capital
+144%$176.4MAccounts Receivables
+145%$16.8BOther Working Capital
-154.3%-$67.2MOther Non-Cash Items
+276%$3.4BNet Cash Provided by Operating Activities
+1.9%-$310.0MInvestments in PP&E
-97.1%-$22.4MPurchase of Investments
-96.5%$10.0MSales/Maturities of Investments
-58.7%-$322.4MNet Cash used for Investing Activities
-16.7%-$306.0MCommon Stock Repurchased
-98.9%-$4.8MOther Financing Activities
-60.1%-$295.2MNet Cash Used Provided by Financing Activities
-1,272.3%$80.0MEffect of Exchange Rate Changes on Cash
-544.5%$2.8BNet Change in Cash
+160%$12.1BCash at End of Period
+76.1%$9.3BCash at Beginning of Period
+276%$3.4BOperating Cash Flow
+1.9%-$310.0MCapital Expenditure (capex)
+418%$3.1BFree Cash Flow
  • ALXN Historical Operating Margin Table
    in million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Operating Margin YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 722 -6.9% - -
    4/1/2020 775 28.9% - -
    4/1/2019 601 34.9% - -
    4/1/2018 445 36.0% - -
    4/1/2017 327 27.2% - -
    4/1/2016 257 17.2% - -
    4/1/2015 220 -0.6% - -
    4/1/2014 221 50.5% - -
    4/1/2013 147 51.3% - -
    4/1/2012 97 69.8% - -
    4/1/2011 57 59.2% - -
    4/1/2010 35 56.3% - -
    4/1/2009 22 693.4% - -
    4/1/2008 2 -110.1% - -
    4/1/2007 -28 4.7% - -
    4/1/2006 -27 -8.7% - -
    4/1/2005 -30 72.8% - -
    4/1/2004 -17 -9.1% - -
    4/1/2003 -19 9.6% - -
    4/1/2002 -17 119.9% - -
    4/1/2001 -7 29.8% - -
    4/1/2000 -6 967.9% - -
    4/1/1999 0 -83.4% - -
    4/1/1998 -3 207.8% - -
    4/1/1997 -1 -29.7% - -
    4/1/1996 -1 45.5% - -
    4/1/1995 -1 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
  • Operating Margin = (EBIT)/(Net sales)
    Measures profitability independently of an enterprise's financing and tax positions

    For more detailed definitions, please see Investopedia.
    Year Operating Margin YoY % Change Stock Price YoY % Change (Stock Price) ebitda non d n a net revenue
    4/1/2021 722099999.95 -6.9% 2888.40 300.40 6367.20
    4/1/2020 775824999.94 28.9% 3103.30 344.90 5862.40
    4/1/2019 601674999.92 34.9% 2406.70 384.60 4735.60
    4/1/2018 445874999.87 36.0% 1783.50 492.60 3912.50
    4/1/2017 327959999.88 27.2% 1311.84 411.68 3440.11
    4/1/2016 257806333.20 17.2% 1031.23 384.45 2873.36
    4/1/2015 220052749.96 -0.6% 880.21 91.41 2502.66
    4/1/2014 221306499.98 50.5% 885.23 36.85 2076.17
    4/1/2013 147010749.98 51.3% 588.04 26.51 1429.96
    4/1/2012 97137749.98 69.8% 388.55 22.03 1041.15
    4/1/2011 57194749.98 59.2% 228.78 17.13 711.85
    4/1/2010 35916249.97 56.3% 143.66 15.40 495.63
    4/1/2009 22985249.97 693.4% 91.94 11.01 353.55
    4/1/2008 2896999.96 -110.1% 11.59 7.25 215.56
    4/1/2007 -28799687.67 4.7% -122.64 4.26 43.11
    4/1/2006 -27510688.97 -8.7% -115.78 3.30 6.67
    4/1/2005 -30145003.84 72.8% -120.58 3.86 1.38
    4/1/2004 -17448754.13 -9.1% -69.80 3.54 4.61
    4/1/2003 -19200880.38 9.6% -77.45 3.71 0.69
    4/1/2002 -17520501.41 119.9% -70.08 3.52 5.00
    4/1/2001 -7968250.56 29.8% -31.87 5.54 10.12
    4/1/2000 -6140250.15 967.9% -24.56 2.28 18.43
    4/1/1999 -575000.05 -83.4% -8.10 1.10 34.05
    4/1/1998 -3462500.45 207.8% -14.70 0.70 7.35
    4/1/1997 -1125000.14 -29.7% -4.50 0.60 7.00
    4/1/1996 -1600000.19 45.5% -6.40 0.53 2.93
    4/1/1995 -1100000.40 -4.40 0.80 2.00